Muhammad Imran Khan

Dr. Muhammad Imran Khan

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
MKMuhammad Imran Khan
Muhammad Imran Khan
Nina FilipczakNina Filipczak
Nina Filipczak
VTVladimir P. Torchilin
Vladimir P. Torchilin

1 January 2019 in Drug Delivery
Verified
Journal Article
Open access
MKMuhammad Imran Khan
Muhammad Imran Khan
MMM. Asadullah Madni
M. Asadullah Madni
VTVladimir Torchilin
Vladimir Torchilin
Nina FilipczakNina Filipczak
Nina Filipczak
JPJiayi Pan
Jiayi Pan
HSHassan Shah
Hassan Shah
Lipid-polymer hybrid nanoparticles (LPHNP) are delivery systems for controlled drug delivery at tumor sites. The superior biocompatible properties of lipids and structural advantages of polymers can be obtained using this system for controlled drug delivery. In this study, cisplatin-loaded lipid-chitosan hybrid nanoparticles were formulated by the single step ionic gelation method based on ionic interaction of positively charged chitosan and negatively charged lipid. Formulations with various chitosan to lipid ratios were investigated to obtain the optimal particle size, encapsulation efficiency, and controlled release pattern. Transmission electron microscope and dynamic light scattering analysis demonstrated a size range of 181–245 nm and a zeta potential range of 20–30 mV. The stability of the formulation was demonstrated by thermal studies. Cytotoxicity and cellular interaction of cisplatin-loaded LPHNP were investigated using in vitro cell-based assays using the A2780 ovarian carcinoma cell line. The pharmacokinetics study in rabbits supported a controlled delivery of cisplatin with enhanced mean residence time and half-life. These studies suggest that cisplatin loaded LPHNP have promise as a platform for controlled delivery of cisplatin in cancer therapy.

17 February 2022 in Drug Delivery
Verified
Journal Article
Open access
UGUzma Gul
Uzma Gul
MKMuhammad Imran Khan
Muhammad Imran Khan
AMAsadullah Madni
Asadullah Madni
MSMuhammad Farhan Sohail
Muhammad Farhan Sohail
MRMubashar Rehman
Mubashar Rehman
LPLeena Peltonen
Leena Peltonen
In this article, formulation studies for terbinafine hydrochloride nanoemulsions, prepared by high-energy ultrasonication technique, are described. Pseudo-ternary phase diagram was constructed in order to find out the optimal ratios of oil and surfactant/co-solvent mixture for nanoemulsion production. Clove and olive oils were selected as oil phase. Based on the droplet size evaluation, maximum nanoemulsion region were determined for formulation development. Further characterization included polydispersity index (PDI), zeta potential, Fourier transform infrared (FT-IR) spectroscopy, morphology, pH, viscosity, refractive index, ex vivo skin permeation, skin irritation, and histopathological examination. Droplet sizes of optimized formulations were in colloidal range. PDI values below 0.35 indicated considerably homogeneous nanoemulsions. Zeta potential values were from 13.2 to 18.1 mV indicating good stability, which was also confirmed by dispersion stability studies. Ex vivo permeation studies revealed almost total skin permeation of terbinafine hydrochloride from the nanoemulsions (96–98%) in 6 hours whereas commercial product reached only 57% permeation at the same time. Maximum drug amounts were seen in epidermis and dermis layers. Skin irritation and histopathological examination demonstrated dermatologically safe formulations. In conclusion, olive oil and clove oil-based nanoemulsion systems have potential to serve as promising carriers for topical terbinafine hydrochloride delivery.

1 March 2020 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
MKMuhammad Imran Khan
Muhammad Imran Khan
MMM. Asadullah Madni
M. Asadullah Madni
NTNayab Tahir
Nayab Tahir
FPFarzana Parveen
Farzana Parveen
SKSafiullah Khan
Safiullah Khan
MKMuhammad Imran Khan
Muhammad Imran Khan
Background: Lipid-polymer hybrid nanoparticles (LPHNP) are suitable for co-delivery of hydrophilic and lipophilic drugs. The structural advantages of polymers and biomimetic properties of lipids enable higher encapsulation of drugs and controlled release profile. Lipid-polymer hybrid nanoparticles have been prepared for co-delivery of curcumin and cisplatin for enhanced cytotoxicity against ovarian cancer. Material and Methods: Chitosan, cisplatin, curcumin, Lipoid S75 were selected as structural components and ionic gelation method was used for preparation of LPHNPs. Nanoparticles were formed via ionic interaction of positively charged chitosan and negatively charged lipid. Results: The optimized nanoparticles were of 225 nm with cationic charge. The encapsulation efficiency was greater than 80% with good drug loading. The drug release profile showed controlled release behavior of both curcumin and cisplatin simultaneously and the absence of burst release. The in vitro therapeutic efficacy and cellular association was evaluated using A2780 ovarian cell lines. To further investigate therapeutic efficacy, we developed 3D spheroids as tumor model to mimic the in vivo conditions. The cytotoxicity and uptake of co-loaded LPHNPs were evaluated on 3D spheroids and results indicated increased chemosensitization and enhanced therapeutic efficacy of co-loaded LPHNPs. Conclusion: Lipid-polymer hybrid nanoparticles could be a suitable platform for co-delivery of curcumin and cisplatin for enhanced cytotoxic effect on ovarian cell lines.

29 November 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MKMuhammad Imran Khan
Muhammad Imran Khan
SYSamiya Yaqoob
Samiya Yaqoob
AMAsadullah Madni
Asadullah Madni
MAMuhammad Furqan Akhtar
Muhammad Furqan Akhtar
MSMuhammad Farhan Sohail
Muhammad Farhan Sohail
OQOmer Salman Qureshi
Omer Salman Qureshi
Transfersomes (TFS) are the promising carriers for transdermal delivery of various low and high molecular weight drugs, owing to their self‐regulating and self‐optimizing nature. Herein, we report synthesis and characterization of TFS loaded with meloxicam (MLX), an NSAID, and dexamethasone (DEX), a steroid, for simultaneous transdermal delivery. The different formulations of TFS containing varying amounts of lecithin, Span 80, and Tween 80 (TFS‐1 to TFS‐6) were successfully prepared by thin‐film hydration method. The size of ranged between 248 and 273 nm, zeta potential values covering from –62.6 to –69.5 mV, polydispersity index (PDI) values in between 0.329 and 0.526, and entrapment efficiency of MLX and DEX ranged between 63‐96% and 48‐81%, respectively. Release experiments at pH 7.4 demonstrated higher cumulative drug release attained with Tween 80 compared to Span 80‐based TFS. The scanning electron microscopy (SEM) of selected formulations ‐1 and TFS‐3 revealed spherical shape of vesicles. Furthermore, three optimized transfersomal formulations (based on entrapment efficiency, TFS‐1, TFS‐3, and TFS‐5) were incorporated into carbopol‐940 gels coded as TF‐G1, TF‐G3, and TF‐G5. These transfersomal gels were subjected to pH, spreadability, viscosity, homogeneity, skin irritation, in vitro drug release, and ex vivo skin permeation studies, and the results were compared with plain (nontransfersomal) gel having MLX and DEX. TFS released 71.72% to 81.87% MLX in 12 h; whereas, DEX release was quantified as 74.72% to 83.72% in same time. Nevertheless, TF‐based gels showed slower drug release; 51.54% to 59.60% for MLX and 48.98% to 61.23% for DEX. The TF‐G systems showed 85.87% permeation of MLX (TF‐G1), 68.15% (TF‐G3), and 68.94% (TF‐G5); whereas, 78.59%, 70.54%, and 75.97% of DEX was permeated by TF‐G1, TF‐G3, and TF‐G5, respectively. Kinetic modeling of release and permeation data indicated to follow Korsmeyer‐Peppas model showing diffusion diffusion‐based drug moment. Conversely, plain gel influx was found mere 26.18% and 22.94% for MLX and DEX, respectively. These results suggest that TF‐G loaded with MLX and DEX can be proposed as an alternate drug carriers for improved transdermal flux that will certainly increase therapeutic outcomes.

1 August 2020 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
MKMuhammad Imran Khan
Muhammad Imran Khan
AMAsadullah Madni
Asadullah Madni
Nina FilipczakNina Filipczak
Nina Filipczak
JPJiayi Pan
Jiayi Pan
MRMubashar Rehman
Mubashar Rehman
VTVladimir P. Torchilin
Vladimir P. Torchilin